Your request to link to rcsb for ATIII/alphaIIa

• 1D3D: crystal structure of human alpha thrombin in complex with benzothiophene inhibitor 4
• 1D3P: crystal structure of human aplha-thrombin in complex with benzo[b]thiophene inhibitor 3
• 1D3Q: crystal structure of human alpha thrombin in complex with benzo[b]thiophene inhibitor 2
• 1D3T: crystal structure of human alpha thrombin in complex with benzo[b]thiophene inhibitor 1
• 1D4P: crystal structure of human alpha thrombin in complex with 5- amidinoindole-4-benzylpiperidine inhibitor
• 1D6W: structure of thrombin complexed with selective non-electrophilic inhibitors having cyclohexyl moieties at p1 (10.1107/S0907444900000068 )
• 1D9I: structure of thrombin complexed with selective non-electophilic inhibitors having cyclohexyl moieties at p1 (10.1107/S0907444900000068 )
• 1DE7: interaction of factor xiii activation peptide with alpha-thrombin: crystal structure of the enzyme-substrate complex (10.1074/JBC.M006076200 )
• 1DIT: complex of a divalent inhibitor with thrombin
• 1DM4: ser195ala mutant of human thrombin complexed with fibrinopeptide a (7- 16) 17-mar-00 1dm4 1 remark seqres atom title (10.1107/S0907444900001487 )
• 1DOJ: crystal structure of human alpha-thrombin*rwj-51438 complex at 1.7 a (10.1107/S0907444900010763 )
• 1DWB: crystallographic analysis at 3.0-angstroms resolution of the binding to human thrombin of four active site-directed inhibitors
• 1DWC: crystallographic analysis at 3.0-angstroms resolution of the binding to human thrombin of four active site-directed inhibitors
• 1DWD: crystallographic analysis at 3.0-angstroms resolution of the binding to human thrombin of four active site-directed inhibitors
• 1DWE: crystallographic analysis at 3.0-angstroms resolution of the binding to human thrombin of four active site-directed inhibitors
• 1DX5: crystal structure of the thrombin-thrombomodulin complex (10.1038/35006683 )
• 1DZG: n135q-s380c-antithrombin-iii (10.1074/JBC.275.20.15377 )
• 1DZH: p14-fluorescein-n135q-s380c-antithrombin-iii (10.1074/JBC.275.20.15377 )
• 1E03: plasma alpha antithrombin-iii and pentasaccharide (10.1016/S0022-2836(02)01382-7 )
• 1E04: plasma beta antithrombin-iii (10.1016/S0022-2836(02)01382-7 )
• 1E05: plasma alpha antithrombin-iii (10.1016/S0022-2836(02)01382-7 )
• 1E0F: crystal structure of the human alpha-thrombin-haemadin complex: an exosite ii-binding inhibitor (10.1093/EMBOJ/19.21.5650 )
• 1EB1: complex structure of human thrombin with n-methyl-arginine inhibitor (10.1006/JMBI.2001.5394 )
• 1EOJ: design of p1' and p3' residues of trivalent thrombin inhibitors and their crystal structures (10.1021/BI992419B )
• 1EOL: design of p1' and p3' residues of trivalent thrombin inhibitors and their crystal structures (10.1021/BI992419B )
• 1ETR: refined 2.3 angstroms x-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors napap, 4-tapap and mqpa: a starting point for improving antithrombotics (10.1016/0022-2836(92)91054-S )
• 1ETS: refined 2.3 angstroms x-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors napap, 4-tapap and mqpa: a starting point for improving antithrombotics (10.1016/0022-2836(92)91054-S )
• 1ETT: refined 2.3 angstroms x-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors napap, 4-tapap and mqpa: a starting point for improving antithrombotics (10.1016/0022-2836(92)91054-S )
• 1FPC: active site mimetic inhibition of thrombin (10.1107/S0907444994013132 )
• 1FPH: the interaction of thrombin with fibrinogen: a structural basis for its specificity (10.1111/J.1432-1033.1992.TB16916.X )
• 1G30: thrombin inhibitor complex (10.1016/S0969-2126(00)00551-7 )
• 1G32: thrombin inhibitor complex (10.1016/S0969-2126(00)00551-7 )
• 1G37: crystal structure of human alpha-thrombin complexed with bch-10556 and exosite-directed peptide (10.1016/S0960-894X(00)00636-3 )
• 1GHV: a novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site (10.1006/JMBI.2001.4516 )
• 1GHW: a novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site (10.1006/JMBI.2001.4516 )
• 1GHX: a novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site (10.1006/JMBI.2001.4516 )
• 1GHY: a novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site (10.1006/JMBI.2001.4516 )
• 1GJ4: selectivity at s1, h2o displacement, upa, tpa, ser190/ala190 protease, structure-based drug design (10.1016/S1074-5521(01)00084-9 )
• 1GJ5: selectivity at s1, h2o displacement, upa, tpa, ser190/ala190 protease, structure-based drug design (10.1016/S1074-5521(01)00084-9 )
• 1H8D: x-ray structure of the human alpha-thrombin complex with a tripeptide phosphonate inhibitor. (10.1006/JMBI.2001.4872 )
• 1H8I: x-ray crystal structure of human alpha-thrombin with a tripeptide phosphonate inhibitor. (10.1006/JMBI.2001.4872 )
• 1HAG: the isomorphous structures of prethrombin2, hirugen-and ppack- thrombin: changes accompanying activation and exosite binding to thrombin
• 1HAH: the isomorphous structures of prethrombin2, hirugen-and ppack- thrombin: changes accompanying activation and exosite binding to thrombin
• 1HAI: the isomorphous structures of prethrombin2, hirugen-and ppack- thrombin: changes accompanying activation and exosite binding to thrombin
• 1HAO: complex of human alpha-thrombin with a 15mer oligonucleotide ggttggtgtggttgg (based on nmr model of dna) (10.1107/S0907444995013977 )
• 1HAP: complex of human alpha-thrombin with a 15mer oligonucleotide ggttggtgtggttgg (based on x-ray model of dna) (10.1107/S0907444995013977 )
• 1HBT: human alpha-thrombin complexed with a peptidyl pyridinium methyl ketone containing bivalent inhibitor (10.1021/BI00036A029 )
• 1HDT: structure of a retro-binding peptide inhibitor complexed with human alpha-thrombin (10.1006/JMBI.1994.0060 )
• 1HGT: structure of the hirugen and hirulog 1 complexes of alpha- thrombin (10.1016/0022-2836(91)80132-E )
• 1HLT: the structure of a nonadecapeptide of the fifth egf domain of thrombomodulin complexed with thrombin (10.1021/BI00250A006 )
• 1HRT: the structure of a complex of bovine alpha-thrombin and recombinant hirudin at 2.8 angstroms resolution
• 1HUT: the structure of alpha-thrombin inhibited by a 15-mer single-stranded dna aptamer
• 1HXE: serine protease (10.1016/S0301-4622(96)02227-2 )
• 1HXF: human thrombin complex with hirudin variant (10.1016/S0301-4622(96)02227-2 )
• 1ID5: crystal structure of bovine thrombin complex with protease inhibitor ecotin (10.1021/BI010712H )
• 1IHS: crystal structure of the complex of human alpha-thrombin and non- hydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6 (10.1002/PROT.340170304 )
• 1IHT: crystal structure of the complex of human alpha-thrombin and non- hydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6 (10.1002/PROT.340170304 )
• 1JMO: crystal structure of the heparin cofactor ii-s195a thrombin complex (10.1073/PNAS.162232399 )
• 1JOU: crystal structure of native s195a thrombin with an unoccupied active site (10.1016/S0969-2126(03)00049-2 )
• 1JVQ: crystal structure at 2.6a of the ternary complex between antithrombin, a p14-p8 reactive loop peptide, and an exogenous tetrapeptide (10.1016/J.JMB.2004.07.078 )
• 1JWT: crystal structure of thrombin in complex with a novel bicyclic lactam inhibitor (10.1016/S0960-894X(01)00661-8 )
• 1K21: human thrombin-inhibitor complex (10.1006/JMBI.2001.5062 )
• 1K22: human thrombin-inhibitor complex (10.1006/JMBI.2001.5062 )
• 1KTS: thrombin inhibitor complex (10.1021/JM0109513 )
• 1KTT: thrombin inhibitor complex (10.1021/JM0109513 )
• 1LHC: human alpha-thrombin complexed with ac-(d)phe-pro-boroarg-oh (10.1021/BI00011A033 )
• 1LHD: human alpha-thrombin complexed with ac-(d)phe-pro-borolys-oh (10.1021/BI00011A033 )
• 1LHE: human alpha-thrombin complexed with ac-(d)phe-pro-boro-n- butyl-amidino-glycine-oh (10.1021/BI00011A033 )
• 1LHF: human alpha-thrombin complexed with ac-(d)phe-pro-boro- homolys-oh (10.1021/BI00011A033 )
• 1LHG: human alpha-thrombin complexed with ac-(d)phe-pro- boroornithine-oh (10.1021/BI00011A033 )
• 1LK6: structure of dimeric antithrombin complexed with a p14-p9 reactive loop peptide and an exogenous tripeptide (10.1074/JBC.M211663200 )
• 1MH0: crystal structure of the anticoagulant slow form of thrombin (10.1074/JBC.C200465200 )
• 1MKW: the co-crystal structure of unliganded bovine alpha- thrombin and prethrombin-2: movement of the yppw segment and active site residues upon ligand binding
• 1MKX: the co-crystal structure of unliganded bovine alpha- thrombin and prethrombin-2: movement of the yppw segment and active site residues upon ligand binding
• 1MU6: crystal structure of thrombin in complex with l-378,622 (10.1021/JM020311F )
• 1MU8: thrombin-hirugen_l-378,650 (10.1021/JM020311F )
• 1MUE: thrombin-hirugen-l405,426 (10.1016/S0960-894X(03)00099-4 )
• 1NM6: thrombin in complex with selective macrocyclic inhibitor at 1.8a (10.1016/S0960-894X(03)00506-7 )
• 1NO9: design of weakly basic thrombin inhibitors incorporating novel p1 binding functions: molecular and x-ray crystallographic studies. (10.1021/BI020512L )
• 1NQ9: crystal structure of antithrombin in the pentasaccharide-bound intermediate state (10.1021/BI034524Y )
• 1NRN: crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes (10.1021/BI00177A018 )
• 1NRO: crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes (10.1021/BI00177A018 )
• 1NRP: crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes (10.1021/BI00177A018 )
• 1NRQ: crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes (10.1021/BI00177A018 )
• 1NRR: crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes (10.1021/BI00177A018 )
• 1NRS: crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes (10.1021/BI00177A018 )
• 1NT1: thrombin in complex with selective macrocyclic inhibitor (10.1016/S0960-894X(03)00506-7 )
• 1NU7: staphylocoagulase-thrombin complex (10.1038/NATURE01962 )
• 1NU9: staphylocoagulase-prethrombin-2 complex (10.1038/NATURE01962 )
• 1NY2: human alpha thrombin inhibited by rppgf and hirugen (10.1152/AJPHEART.00490.2002 )
• 1NZQ: d-phe-pro-arg-type thrombin inhibitor (10.1016/S0960-894X(03)00236-1 )
• 1O0D: human thrombin complexed with a d-phe-pro-arg-type inhibitor and a c- terminal hirudin derived exo-site inhibitor (10.1016/S0960-894X(03)00236-1 )
• 1O2G: elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors (10.1016/S0022-2836(03)00399-1 )
• 1O5G: dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa) (10.1016/J.JMB.2004.09.032 )
• 1OOK: crystal structure of the complex of platelet receptor gpib-alpha and human alpha-thrombin (10.1126/SCIENCE.1084183 )
• 1OYH: crystal structure of p13 alanine variant of antithrombin (10.1074/JBC.M311644200 )
• 1OYT: complex of recombinant human thrombin with a designed fluorinated inhibitor (10.1002/ANIE.200351268 )
• 1P8V: crystal structure of the complex of platelet receptor gpib-alpha and alpha-thrombin at 2.6a (10.1126/SCIENCE.1083917 )
• 1PPB: the refined 1.9 angstroms crystal structure of human alpha-thrombin: interaction with d-phe-pro-arg chloromethylketone and significance of the tyr-pro-pro-trp insertion segment
• 1QBV: crystal structure of thrombin complexed with an guanidine-mimetic inhibitor (10.1021/JM970796L )
• 1QHR: novel covalent active site thrombin inhibitors (10.1021/BI9830359 )
• 1QJ1: novel covalent active site thrombin inhibitors (10.1021/BI9830359 )
• 1QJ6: novel covalent active site thrombin inhibitors 30-may-18 1qj6 1 title (10.1021/BI9830359 )
• 1QJ7: novel covalent active site thrombin inhibitors 30-may-18 1qj7 1 title (10.1021/BI9830359 )
• 1QUR: human alpha-thrombin in complex with bivalent, benzamidine-based synthetic inhibitor (10.1046/J.1432-1327.1999.00742.X )
• 1R1L: structure of dimeric antithrombin complexed with a p14-p9 reactive loop peptide and an exogenous tripeptide (formyl-norleucine-lf)
• 1RD3: 2.5a structure of anticoagulant thrombin variant e217k (10.1074/JBC.M402364200 )
• 1RIW: thrombin in complex with natural product inhibitor oscillarin (10.1021/JA030669G )
• 1SB1: novel non-covalent thrombin inhibitors incorporating p1 4,5,6,7- tetrahydrobenzothiazole arginine side chain mimetics (10.1016/J.EJMECH.2003.12.006 )
• 1SFQ: fast form of thrombin mutant r(77a)a bound to ppack (10.1074/JBC.M401756200 )
• 1SG8: crystal structure of the procoagulant fast form of thrombin (10.1074/JBC.M401756200 )
• 1SGI: crystal structure of the anticoagulant slow form of thrombin (10.1074/JBC.M401756200 )
• 1SHH: slow form of thrombin bound with ppack (10.1074/JBC.M401756200 )
• 1SL3: crystal structue of thrombin in complex with a potent p1 heterocycle- aryl based inhibitor (10.1021/JM030303E )
• 1SR5: antithrombin-anhydrothrombin-heparin ternary complex structure (10.1074/JBC.M406135200 )
• 1T1F: crystal structure of native antithrombin in its monomeric form (10.1074/JBC.M607204200 )
• 1T4U: crystal structure analysis of a novel oxyguanidine bound to thrombin (10.1016/J.BMCL.2004.05.002 )
• 1T4V: crystal structure analysis of a novel oxyguanidine bound to thrombin (10.1016/J.BMCL.2004.05.002 )
• 1TA2: crystal structure of thrombin in complex with compound 1 (10.1021/JM9801713 )
• 1TA6: crystal structure of thrombin in complex with compound 14b (10.1021/JM9801713 )
• 1TB6: 2.5a crystal structure of the antithrombin-thrombin-heparin ternary complex (10.1038/NSMB811 )
• 1TBQ: crystal structure of insect derived double domain kazal inhibitor rhodniin in complex with thrombin
• 1TBR: crystal structure of insect derived double domain kazal inhibitor rhodniin in complex with thrombin
• 1TBZ: human thrombin with active site n-methyl-d phenylalanyl-n-[5- (aminoiminomethyl)amino]-1-{{benzothiazolyl)carbonyl] butyl]-l- prolinamide trifluroacetate and exosite-hirugen
• 1THP: structure of human alpha-thrombin y225p mutant bound to d-phe-pro-arg- chloromethylketone (10.1073/PNAS.96.5.1852 )
• 1THR: structures of thrombin complexes with a designed and a natural exosite inhibitor
• 1THS: structures of thrombin complexes with a designed and a natural exosite inhibitor
• 1TMB: molecular basis for the inhibition of human alpha-thrombin by the macrocyclic peptide cyclotheonamide a (10.1073/PNAS.90.17.8048 )
• 1TMT: changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms
• 1TMU: changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms
• 1TOC: structure of serine proteinase
• 1TOM: alpha-thrombin complexed with hirugen
• 1TQ0: crystal structure of the potent anticoagulant thrombin mutant w215a/e217a in free form (10.1074/JBC.M407272200 )
• 1TQ7: crystal structure of the anticoagulant thrombin mutant w215a/e217a bound to ppack (10.1074/JBC.M407272200 )
• 1TWX: crystal structure of the thrombin mutant d221a/d222k (10.1016/J.BPC.2004.07.027 )
• 1UCY: thrombin complexed with fibrinopeptide a alpha (residues 7- 19). three complexes, one with epsilon-thrombin and two with alpha-thrombin (10.1021/BI960656Y )
• 1UMA: alpha-thrombin (hirugen) complexed with na-(n,n-dimethylcarbamoyl)- alpha-azalysine (10.1006/JMBI.1996.0292 )
• 1UVS: bovine thrombin--bm51.1011 complex (10.1016/S0969-2126(96)00142-6 )
• 1UVT: bovine thrombin--bm14.1248 complex (10.1016/S0969-2126(96)00142-6 )
• 1UVU: bovine thrombin--bm12.1700 complex (10.1016/S0969-2126(96)00142-6 )
• 1VIT: thrombin:hirudin 51-65 complex (10.1107/S0907444996000364 )
• 1VR1: specifity for plasminogen activator inhibitor-1 (10.1006/JMBI.1999.3178 )
• 1VZQ: complex of thrombin with designed inhibitor 7165
• 1W7G: alpha-thrombin complex with sulfated hirudin (residues 54-65) and l- arginine template inhibitor cs107 (10.1039/B510239A )
• 1WAY: active site thrombin inhibitors (10.1021/JM0495778 )
• 1WBG: active site thrombin inhibitors (10.1021/JM0495778 )
• 1XM1: nonbasic thrombin inhibitor complex
• 1XMN: crystal structure of thrombin bound to heparin (10.1074/JBC.M411606200 )
• 1YCP: the crystal structure of fibrinogen-aa peptide 1-23 (f8y) bound to bovine thrombin explains why the mutation of phe-8 to tyrosine strongly inhibits normal cleavage at arginine-16
• 1YPE: thrombin inhibitor complex (10.1002/ANIE.200502302 )
• 1YPG: thrombin inhibitor complex (10.1002/ANIE.200502302 )
• 1YPJ: thrombin inhibitor complex (10.1002/ANIE.200502302 )
• 1YPK: thrombin inhibitor complex (10.1002/ANIE.200502302 )
• 1YPL: x-ray crystal structure of thrombin inhibited by synthetic cyanopeptide analogue ra-1008
• 1YPM: x-ray crystal structure of thrombin inhibited by synthetic cyanopeptide analogue ra-1014
• 1Z71: thrombin and p2 pyridine n-oxide inhibitor complex structure (10.1016/J.BMCL.2005.03.110 )
• 1Z8I: crystal structure of the thrombin mutant g193a bound to ppack (10.1074/JBC.M503499200 )
• 1Z8J: crystal structure of the thrombin mutant g193p bound to ppack (10.1074/JBC.M503499200 )
• 1ZGI: thrombin in complex with an oxazolopyridine inhibitor 21 (10.1016/J.BMCL.2005.07.022 )
• 1ZGV: thrombin in complex with an oxazolopyridine inhibitor 2 (10.1016/J.BMCL.2005.07.022 )
• 1ZRB: thrombin in complex with an azafluorenyl inhibitor 23b (10.1021/JM049423S )
• 2A0Q: structure of thrombin in 400 mm potassium chloride (10.1074/JBC.C500248200 )
• 2A1D: staphylocoagulase bound to bovine thrombin (10.1074/JBC.M507957200 )
• 2A2X: orally active thrombin inhibitors in complex with thrombin inh12 (10.1016/J.BMCL.2006.01.046 )
• 2A45: crystal structure of the complex between thrombin and the central "e" region of fibrin (10.1021/BI0525369 )
• 2AFQ: 1.9 angstrom crystal structure of wild-type human thrombin in the sodium free state 14-dec-16 2afq 1 title (10.1042/BJ20051217 )
• 2ANK: orally active thrombin inhibitors in complex with thrombin and an exosite decapeptide (10.1016/J.BMCL.2006.01.046 )
• 2ANM: ternary complex of an orally active thrombin inhibitor with human thrombin and a c-terminal hirudin derived exo-sit inhibitor (10.1016/J.BMCL.2006.01.046 )
• 2ANT: the 2.6 a structure of antithrombin indicates a conformational change at the heparin binding site (10.1006/JMBI.1996.0798 )
• 2B4X: crystal structure of antithrombin-iii 31-oct-06 2b4x 1 title 17-oct-06 2b4x 1 title
• 2B5T: 2.1 angstrom structure of a nonproductive complex between antithrombin, synthetic heparin mimetic sr123781 and two s195a thrombin molecules (10.1074/JBC.M607204200 )
• 2BDY: thrombin in complex with inhibitor (10.1016/J.BMCL.2005.10.082 )
• 2BEH: crystal structure of antithrombin variant s137a/v317c/t401c with plasma latent antithrombin (10.1074/JBC.M607204200 )
• 2BVR: human thrombin complexed with fragment-based small molecules occupying the s1 pocket (10.2174/157018005774717343 )
• 2BVS: human thrombin complexed with fragment-based small molecules occupying the s1 pocket
• 2BVX: design and discovery of novel, potent thrombin inhibitors with a solubilizing cationic p1-p2-linker (10.2174/157018006777574203 )
• 2BXT: design and discovery of novel, potent thrombin inhibitors with a solubilizing cationic p1-p2-linker (10.2174/157018006777574203 )
• 2BXU: design and discovery of novel, potent thrombin inhibitors with a solubilizing cationic p1-p2-linker (10.2174/157018006777574203 )
• 2C8W: thrombin inhibitors (10.1021/JM050850V )
• 2C8X: thrombin inhibitors (10.1021/JM050850V )
• 2C8Y: thrombin inhibitors (10.1021/JM050850V )
• 2C8Z: thrombin inhibitors (10.1021/JM050850V )
• 2C90: thrombin inhibitors (10.1021/JM050850V )
• 2C93: thrombin inhibitors (10.1021/JM050850V )
• 2CF8: complex of recombinant human thrombin with an inhibitor 29-mar-17 2cf8 1 title (10.1039/B602585D )
• 2CF9: complex of recombinant human thrombin with an inhibitor 29-mar-17 2cf9 1 title (10.1039/B602585D )
• 2CN0: complex of recombinant human thrombin with a designed inhibitor (10.1002/CMDC.200600124 )
• 2FEQ: orally active thrombin inhibitors (10.1016/J.BMCL.2006.02.040 )
• 2FES: orally active thrombin inhibitors (10.1016/J.BMCL.2006.02.040 )
• 2GD4: crystal structure of the antithrombin-s195a factor xa-pentasaccharide complex (10.1038/SJ.EMBOJ.7601089 )
• 2GDE: thrombin in complex with inhibitor (10.1021/JA0625834 )
• 2GP9: crystal structure of the slow form of thrombin in a self- inhibited conformation (10.1074/JBC.M605530200 )
• 2H9T: crystal structure of human alpha-thrombin in complex with suramin (10.1016/J.BBAPAP.2009.03.011 )
• 2HGT: structure of the hirugen and hirulog 1 complexes of alpha-thrombin (10.1016/0022-2836(91)80132-E )
• 2HIJ: crystal structure of p14 alanine variant of antithrombin
• 2HNT: crystallographic structure of human gamma-thrombin
• 2HPP: structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human ppack-thrombin (10.1021/BI00069A006 )
• 2HPQ: structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human ppack-thrombin (10.1021/BI00069A006 )
• 2HWL: crystal structure of thrombin in complex with fibrinogen gamma' peptide (10.1016/J.BPC.2006.08.005 )
• 2JH0: human thrombin hirugen inhibitor complex (10.1016/J.BMCL.2007.02.034 )
• 2JH5: human thrombin hirugen inhibitor complex (10.1016/J.BMCL.2007.02.034 )
• 2JH6: human thrombin hirugen inhibitor complex (10.1016/J.BMCL.2007.02.034 )
• 2OCV: structural basis of na+ activation mimicry in murine thrombin (10.1074/JBC.M701323200 )
• 2OD3: human thrombin chimera with human residues 184a, 186, 186a, 186b, 186c and 222 replaced by murine thrombin equivalents. (10.1074/JBC.M701323200 )
• 2ODY: thrombin-bound boophilin displays a functional and accessible reactive-site loop (10.1371/JOURNAL.PONE.0001624 )
• 2PGB: inhibitor-free human thrombin mutant c191a-c220a (10.1074/JBC.M703202200 )
• 2PGQ: human thrombin mutant c191a-c220a in complex with the inhibitor ppack (10.1074/JBC.M703202200 )
• 2PKS: thrombin in complex with inhibitor (10.1039/B705344D )
• 2PUX: crystal structure of murine thrombin in complex with the extracellular fragment of murine par3 (10.1073/PNAS.0704409104 )
• 2PV9: crystal structure of murine thrombin in complex with the extracellular fragment of murine par4 (10.1073/PNAS.0704409104 )
• 2PW8: crystal structure of sulfo-hirudin complexed to thrombin (10.1021/JA0735002 )
• 2R2M: 2-(2-chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors (10.1016/J.BMCL.2007.09.013 )
• 2THF: structure of human alpha-thrombin y225f mutant bound to d-phe-pro-arg- chloromethylketone (10.1073/PNAS.96.5.1852 )
• 2UUF: thrombin-hirugen binary complex at 1.26a resolution (10.1107/S0907444907029976 )
• 2UUJ: thrombin-hirugen-gw473178 ternary complex at 1.32a resolution (10.1107/S0907444907029976 )
• 2UUK: thrombin-hirugen-gw420128 ternary complex at 1.39a resolution (10.1107/S0907444907029976 )
• 2V3H: thrombin with 3-cycle no f (10.1126/SCIENCE.1131943 )
• 2V3O: thrombin with 3-cycle with f (10.1126/SCIENCE.1131943 )
• 2ZC9: thrombin in complex with inhibitor (10.1016/J.JMB.2009.06.016 )
• 2ZDA: exploring thrombin s1 pocket (10.1016/J.JMB.2009.06.016 )
• 2ZDV: exploring thrombin s1 pocket
• 2ZF0: exploring thrombin s1 pocket
• 2ZFF: exploring thrombin s1-pocket
• 2ZFP: thrombin inibition (10.1016/J.JMB.2009.06.016 )
• 2ZFQ: exploring thrombin s3 pocket
• 2ZFR: exploring thrombin s3 pocket
• 2ZG0: exploring thrombin s3 pocket
• 2ZGB: thrombin inhibition (10.1016/J.JMB.2010.02.007 )
• 2ZGX: thrombin inhibition (10.1016/J.JMB.2009.06.016 )
• 2ZHE: exploring thrombin s3 pocket
• 2ZHF: exploring thrombin s3 pocket
• 2ZHQ: thrombin inhibition (10.1016/J.JMB.2010.02.007 )
• 2ZHW: exploring thrombin s3 pocket
• 2ZI2: thrombin inhibition (10.1016/J.JMB.2010.02.007 )
• 2ZIQ: thrombin inhibition
• 2ZNH: crystal structure of a domain-swapped serpin dimer (10.1038/NATURE07394 )
• 2ZNK: thrombin inhibition (10.1016/J.JMB.2010.02.007 )
• 2ZO3: bisphenylic thrombin inhibitors (10.1016/J.JMB.2009.06.016 )
• 3B23: crystal structure of thrombin-variegin complex: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors (10.1371/JOURNAL.PONE.0026367 )
• 3B9F: 1.6 a structure of the pci-thrombin-heparin complex (10.1073/PNAS.0711055105 )
• 3BEF: crystal structure of thrombin bound to the extracellular fragment of par1 (10.1073/PNAS.0710894105 )
• 3BEI: crystal structure of the slow form of thrombin in a self_inhibited conformation (10.1073/PNAS.0710894105 )
• 3BF6: thrombin:suramin complex (10.1016/J.BBAPAP.2009.03.011 )
• 3BIU: human thrombin-in complex with ub-thr10 (10.1002/ANIE.200701169 )
• 3BIV: human thrombin-in complex with ub-thr11 (10.1002/ANIE.200701169 )
• 3BV9: structure of thrombin bound to the inhibitor fm19 (10.1111/J.1538-7836.2008.02937.X )
• 3C1K: crystal structure of thrombin in complex with inhibitor 15 (10.1016/J.BMCL.2008.01.098 )
• 3C27: cyanofluorophenylacetamides as orally efficacious thrombin inhibitors
• 3D49: thrombin inhibition
• 3DA9: crystal structure of thrombin in complex with inhibitor (10.1021/JM8011849 )
• 3DD2: crystal structure of an rna aptamer bound to human thrombin (10.1261/RNA.1239308 )
• 3DHK: bisphenylic thrombin inhibitors (10.1016/J.JMB.2009.06.016 )
• 3DT0: understanding thrombin inhibition
• 3DUX: understanding thrombin inhibition (10.1016/J.JMB.2009.06.016 )
• 3E6P: crystal structure of human meizothrombin desf1 (10.1007/S00018-008-8502-7 )
• 3EDX: crystal structure of the w215a/e217a mutant of murine thrombin
• 3EE0: crystal structure of the w215a/e217a mutant of human thrombin (space group p2(1)2(1)2(1))
• 3EGK: knoble inhibitor (10.1002/ANIE.200703323 )
• 3EQ0: thrombin inhibitor
• 3EVJ: intermediate structure of antithrombin bound to the natural pentasaccharide
• 3F68: thrombin inhibition (10.1016/J.JMB.2009.06.016 )
• 3GIC: structure of thrombin mutant delta(146-149e) in the free form (10.1074/JBC.M109.012344 )
• 3GIS: crystal structure of na-free thrombin in complex with thrombomodulin (10.1111/J.1538-7836.2009.03563.X )
• 3HAT: active site mimetic inhibition of thrombin (10.1107/S0907444994013132 )
• 3HK3: crystal structure of murine thrombin mutant w215a/e217a (one molecule in the asymmetric unit) (10.1074/JBC.M109.025403 )
• 3HK6: crystal structure of murine thrombin mutant w215a/e217a (two molecules in the asymmetric unit) (10.1074/JBC.M109.025403 )
• 3HKI: crystal structure of murine thrombin mutant w215a/e217a in complex with the extracellular fragment of human par1 (10.1074/JBC.M109.025403 )
• 3HKJ: crystal structure of human thrombin mutant w215a/e217a in complex with the extracellular fragment of human par1 (10.1074/JBC.M109.025403 )
• 3HTC: the structure of a complex of recombinant hirudin and human alpha-thrombin
• 3JZ1: crystal structure of human thrombin mutant n143p in e:na+ form (10.1074/JBC.M109.069500 )
• 3JZ2: crystal structure of human thrombin mutant n143p in e* form (10.1074/JBC.M109.069500 )
• 3K65: crystal structure of prethombin-2/fragment-2 complex (10.1016/J.BIOCHI.2015.09.013 )
• 3KCG: crystal structure of the antithrombin-factor ixa-pentasaccharide complex (10.1073/PNAS.0910144107 )
• 3LDX: discovery and clinical evaluation of rwj-671818, a thrombin inhibitor with an oxyguanidine p1 motif
• 3LU9: crystal structure of human thrombin mutant s195a in complex with the extracellular fragment of human par1 (10.1074/JBC.M110.115337 )
• 3NXP: crystal structure of human prethrombin-1 (10.1073/PNAS.1010262107 )
• 3P17: thrombin inhibition by pyridin derivatives (10.1016/J.JMB.2012.01.054 )
• 3P6Z: structural basis of thrombin mediated factor v activation: essential role of the hirudin-like sequence glu666-glu672 for processing at the heavy chain-b domain junction (10.1182/BLOOD-2010-10-315309 )
• 3P70: structural basis of thrombin-mediated factor v activation: essential role of the hirudin-like sequence glu666-glu672 for processing at the heavy chain-b domain junction (10.1182/BLOOD-2010-10-315309 )
• 3PMA: 2.2 angstrom crystal structure of the complex between bovine thrombin and sucrose octasulfate (10.1021/BI2004526 )
• 3PMB: 2.9 angstrom crystal structure of bovine thrombin in tetragonal spacegroup (10.1021/BI2004526 )
• 3PMH: mechanism of sulfotyrosine-mediated glycoprotein ib interaction with two distinct alpha-thrombin sites (10.1073/PNAS.1017042108 )
• 3PO1: thrombin in complex with benzothiazole guanidine (10.1016/J.BMCL.2012.05.046 )
• 3QDZ: crystal structure of the human thrombin mutant d102n in complex with the extracellular fragment of human par4.
• 3QGN: the allosteric e*-e equilibrium is a key property of the trypsin fold (10.1021/BI200878C )
• 3QLP: x-ray structure of the complex between human alpha thrombin and a modified thrombin binding aptamer (mtba) (10.1093/NAR/GKR522 )
• 3QTO: thrombin inhibition by pyridin derivatives (10.1016/J.JMB.2012.01.054 )
• 3QTV: thrombin inhibition by pyridin derivatives (10.1016/J.JMB.2012.01.054 )
• 3QWC: thrombin inhibition by pyridin derivatives (10.1016/J.JMB.2012.01.054 )
• 3QX5: thrombin inhibition by pyridin derivatives (10.1016/J.JMB.2012.01.054 )
• 3R3G: structure of human thrombin with residues 145-150 of murine thrombin. (10.1016/J.BPC.2011.04.003 )
• 3RLW: human thrombin in complex with mi328 (10.1021/JM300337Q )
• 3RLY: human thrombin in complex with mi329 (10.1021/JM300337Q )
• 3RM0: human thrombin in complex with mi354 (10.1021/JM300337Q )
• 3RM2: human thrombin in complex with mi003 (10.1021/JM300337Q )
• 3RML: human thrombin in complex with mi331 (10.1021/JM300337Q )
• 3RMM: human thrombin in complex with mi332 (10.1021/JM300337Q )
• 3RMN: human thrombin in complex with mi341 (10.1021/JM300337Q )
• 3RMO: human thrombin in complex with mi004 (10.1021/JM300337Q )
• 3S7H: structure of thrombin mutant y225p in the e* form (10.1021/BI200878C )